Melinta Therapeutics
Industry | Pharmaceutical |
---|---|
Founded | 2000 |
Headquarters | Parsippany, NJ |
Area served | Worldwide |
Products | Broad-spectrum antibiotics |
Website | melinta |
Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. The company is located in Parsippany, New Jersey.[1]
In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics.[2] It was renamed Melinta Therapeutics in 2013.[3]
One of its products, delafloxacin (Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006,[2] was approved by the FDA in 2017.[4]
As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.[3]
Melinta shredded off its discovery research team in late 2018.[5] It also moved its headquarters from New Haven to Morristown, New Jersey in early 2019.
On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.[6]
In April 2020, it was transferred to affiliates of its creditor Deerfield Management.[5]
References
- ^ Carroll, John (2011). "Rib-X Pharmaceuticals - 2011 Fierce 15". FierceBiotech.
- ^ a b Cartwright, Heather (12 July 2011). "Rib-X Pharmaceuticals Signs Global Antibiotic Research Collaboration with Sanofi". PharmaDeals Review. No. 7. doi:10.3833/pdr.v2011i7.1494 (inactive 2024-09-13). Archived from the original on 25 April 2012.
{{cite news}}
: CS1 maint: DOI inactive as of September 2024 (link) - ^ a b Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal.
- ^ Osborne, Randy (20 June 2017). "Melinta's I.V., oral delafloxacin wins FDA nod in skin infections". BioWorld. Archived from the original on 3 August 2019. Retrieved 10 July 2017.
- ^ a b Missakian, Natalie (April 23, 2020). "Antibiotics maker Melinta emerges from bankruptcy under new ownership". Hartford Business. Retrieved 23 November 2022.
- ^ "Antibiotics maker Melinta files for Chapter 11 bankruptcy". Reuters. 2019-12-27. Retrieved 2019-12-29.
External links
- Official website
- v
- t
- e
- Abbott Laboratories
- AbbVie Inc.
- Acorda Therapeutics
- Advaxis
- Alcon
- Alexion
- Alnylam
- Amgen
- Amneal Pharmaceuticals
- Avax Technologies
- Baxter
- BioCryst
- Biogen
- Bioverativ
- Biovest
- Biovista
- Bristol Myers Squibb
- Century
- Ceragenix
- Combe
- CytoSport
- CytRx
- Danco Laboratories
- Eli Lilly
- Galena Biopharma
- Genentech
- Gilead Sciences
- Ionis
- Institute for OneWorld Health
- Intercept
- Johnson & Johnson
- Kinetic Concepts
- McKesson
- Melinta Therapeutics
- Melior Discovery
- Mentholatum
- Merck & Co.
- Merrimack Pharmaceuticals
- Myriad Genetics
- Moderna
- Northwest Biotherapeutics
- Norwich Pharma
- NovaBay
- Organon
- Ovation
- Pfizer
- Pharmaceutical Product Development
- Prasco Laboratories
- Procter & Gamble
- Proteon Therapeutics
- Purdue Pharma
- Quark
- Regeneron
- RespireRx
- Sarepta Therapeutics
- Sheffield
- Spectrum
- Tec Laboratories
- Titan
- Trevena Inc
- Ultragenyx
- Upsher-Smith
- Ventria Bioscience
- Vertex
- Viatris
- West Pharmaceutical Services
Tax inversion |
|
---|---|
Other |
|
40°48′06″N 74°27′31″W / 40.80164°N 74.45860°W / 40.80164; -74.45860